TNYA logo

TENAYA THERAPEUTICS INC

TNYANASDAQ
🏆 #3993 by market capEarnings Nov 11US Equity
$0.40—
Last available close · quote unavailable
🔔
Track TNYA
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d▲ 3.5%
14d▼ 1.7%
30d▼ 32.7%
ytd▼ 43.1%
1y▼ 72.0%
🏦Market Cap
$92M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
263.7%
High
💵FCF Margin
-5380.8%
Thin
⚖️P/S Ratio
69.0x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
—
52-Week Range
$0.36 – $1.70
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
224.2M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
$1M
P/E Ratio
-0.8
P/S Ratio
69.0x
EPS (TTM)
$-0.47
Dividend Yield
0.00%
Dilution (1yr)
+77.0%
TNYA logo

TENAYA THERAPEUTICS INC

TNYA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$93M▼ −19.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$69M▼ −24.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
153.0M▲ +77.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$90M▲ +$99M YoY
StockOtter · stockotter.space

About TENAYA THERAPEUTICS INC

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
12 analysts
Strong Buy3
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.